Improving the boron carrier is one of the biggest challenges in BNCT:
The boron concentration gradient
between tumor and surrounding healthy tissue should be significantly increased.
The absolute amount of boron in the tumor
cells should be significantly increased.
The targeting
of the boron carrier to the tumor cells (carrier cell surface affinity and/or cell internalisation) should be significantly improved.
The kinetics
of the boron carrier should allow for a long retention in the tumor cells.
Tenboron’s lead boron carrier has a high number of boron atoms and an antibody targeting unit that directs the carrier specifically to cancerous cells
Tenboron’s lead boron carrier is administered directly into the tumor, followed by neutron irradiation
Boron Neutron Capture reaction leads to intense local irradiation precisely at the site of boron accumulation, which leads to tumor necrosis
In addition to the lead molecule, Tenboron has two other carrier development programs.
Novel formulation for BPA for improved stability and logistics
A glioma targeting peptide-boron conjugate.
This website uses cookies to ensure that we give you the best experience on our
website.